(PRNewsfoto/Fujifilm)
LEXINGTON, Mass. and IRVINE, Calif., May 12, 2021 /PRNewswire/ -- FUJIFILM Medical Systems U.S.A., Inc., a leading provider of biomarkers to assess the risk for the development of hepatocellular carcinoma (HCC), and Helio Health, an AI-driven healthcare company developing early cancer detection tests, today announced their collaboration to provide a blood-based assay that can help with the earlier detection of liver cancer. Through this relationship, Helio Health’s DNA methylation and biomarker-based blood test technology, recognized as the HelioLiver Test, will leverage Fujifilm’s 510(k)-cleared µTASWako® i30 Immunological test system for liver cancer biomarkers.
Liver cancer is the fastest growing and second deadliest cancer worldwide. According to the American Cancer Society, liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time. Studies show that early detection of liver cancer is critical to successful outcomes with a survival rate that is 12 times higher if caught in early versus late stages. These statistics underscore the need for more advanced solutions and therapies for early liver cancer detection.